方法：对同一时期38例41眼糖尿病患者白内障(观察组)和117例127眼非糖尿病单纯老年白内障患者(对照组)施行超声乳化联合IOL植入术，观察并比较两组的术后疗效和并发症。

结果：观察组术后最佳视力>0.4者共32眼(78.0%)，对照组共110眼(86.6%)，组间比较差异无统计学意义(P>0.05)； 观察组角膜水肿发生率和前房纤维素性渗出发生率分别为31.7%和19.5%，均显著高于对照组，两组间比较差异有统计学意义(P<0.05)； 观察组后囊膜混浊发生率为14.6%，对照组为11.0%，两组间比较差异无统计学意义(P>0.05)。

结论：超声乳化联合IOL植入术治疗糖尿病患者白内障安全可行，与单纯老年性白内障患者的疗效相当。

METHODS: Totally 38 cases(41 eyes)with diabetic cataract(observation group)and 117 cases(127 eyes)with non-diabetic simple senile cataract(control group)in the same period all received phacoemulsification and IOL implantation and the efficacy and postoperative complications were observed and compared.

RESULTS: There were 32 eyes(78.0%)in the observation group and 110 eyes(86.6%)in the control group getting postoperative best-corrected visual acuity>0.4 respectively, the difference between two groups was not significant(P>0.05). The incidence rate of corneal edema and fibrin exudation in the observation group were 31.7% and 19.5% respectively which were significantly higher than the control group, the differences between groups were statistically significant(P<0.05); the incidence rate of posterior capsular opacification was 14.6% in the observation group and 11.0% in the control group, the difference between groups was not significant(P>0.05).

CONCLUSION: The treatment of phacoemulsification and IOL implantation for diabetic cataract is safe and feasible and has the same efficacy with the simple senile cataract.